Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Large Increase in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 547,000 shares, a growth of 102.8% from the December 31st total of 269,700 shares. Approximately 13.8% of the company’s stock are short sold. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 0.4 days.

Allarity Therapeutics Stock Performance

Allarity Therapeutics stock traded down $0.06 during mid-day trading on Friday, reaching $1.12. The company’s stock had a trading volume of 1,919,955 shares, compared to its average volume of 3,516,534. Allarity Therapeutics has a twelve month low of $0.90 and a twelve month high of $288.00. The business has a 50 day moving average price of $1.10 and a 200-day moving average price of $2.46.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.